BioStock: RhoVac appoints new Chief Development Officer

Rhovac’s drug candidate, RV001, is being developed with the goal of targeting and destroying cancer cells with the potential to metastasise  and a crucial phase IIb study is currently underway. With RhoVac’s Chief Operating Officer (COO), Anders Ljungqvist, approaching retirement, some managerial re-organisation is taking place at the company, and, in January, Steffen Wad Jørgensen has joined RhoVac as Chief Development Officer (CDO). BioStock met with Steffen to learn more about him and his new role within RhoVac.

Läs hela artikeln och intervjun på biostock.se: https://www.biostock.se/2020/01/rhovac-appoints-new-chief-development-officer/

Detta är ett pressmeddelande från BioStock – Connecting Innovation & Capital. https://www.biostock.se